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1. Executive Summary 
Nasal drug delivery has served as an alternative to oral and injection treatments for 
respiratory ailments, such as allergies, congestion, and infection (Berger, 2004). Recent 
studies have examined the role various parameters – spray particle size, flow rate in the 
nasal cavity, spray injection angle, injection velocity, material properties of the particle, 
and deposition mechanisms – play in alleviating nasal symptoms. It has been noted that 
certain specifications lead to wasteful drug deposition and ineffective delivery to targeted 
areas (Quraishi et al., 1997). Computational models are vital in optimizing these 
parameters to maximize the drug’s effectiveness in the targeted sinus areas. This study 
focuses on developing a computational model to describe the optimal flow rate, insertion 
angle, spray cone angle, and particle size of Azelastine hydrochloride (Astelin), a 
common anti-histamine drug, required to suppress an immune response while avoiding 
excessive drug application. 
 
Assuming laminar airflow, the nasal cavity was modeled in 2D and divided into four 
regions: the anterior, the middle, the posterior, and escape. Using COMSOL Multiphysics 
3.5a, the model implemented 2D Navier Stokes fluid flow equations and the Lagrangian 
Particle Tracing module to describe the distribution of drug in the nasal cavity. The 
particle deposition in the 4 regions depended on the characteristics of the particles and its 
flow. To validate the model output, the average drug concentration in each nasal cavity 
region was determined and compared with published numerical data analysis by 
Inthavong et al. (2008). We also run a mass transport simulation to observe the change in 
drug concentration in the mucosal layer over time.    
 
Sensitivity analysis focused on average drug concentration to examine the effect of 
insertion angle, flow rate, cone spray angle, and particle diameter on drug deposition in 
the middle and posterior regions. Most drug particles are 50μm in size and it was 
determined that for this size, the combination of a 40 L/min flow rate of a high insertion 
angle of 45° and a large spray cone angle of 90° exhibited 100% optimal deposition in 
the posterior and middle regions. When particle size was decreased at higher flow rates, 
the majority of particles exited the outlet without depositing. For smaller sized particles, a 
lower flow rate of 20 L/min combined with a lower insertion angle of 20° and same spray 
cone angle of 90°, resulted in an optimal particle deposition of 64%.  
 
These findings will allow future designs of nasal sprays to focus on the optimal 
parameters – drug size, flow rate, insertion angle, and spray cone angle. This model can 
pave a way for nasal sprays to be used in medical treatments outside of chronic rhinitis 
and respiratory ailments, such as diabetes and other pain treatments.  
 
Keywords: nasal spray, spray cone angle, drug deposition, Astelin, optimization 
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2. Introduction 
Nasal drug delivery provides an alternative non-invasive method to administer a variety 
of systemic drugs. The intranasal administration of drugs is not a novel concept, but has 
been practiced for centuries. Ancient Tibetans used inhalers containing sandalwood and 
aloewood extracts as antiemetic while Ancient Egyptians resorted to intranasal medicine 
to treat epistaxis and rhinitis (Quraishi et al., 1997). This method of administration 
provides not only convenience to the patients, but also superior rates of drug absorption 
and metabolism in the mucosal lining of the nose. 
 
The rich vasculature and high permeability of the nasal mucosa favor efficient 
pharmacokinetics, thus making it an ideal tissue to target for drug delivery. Factors that 
facilitate transnasal absorption of drugs include the stratified squamous epithelium of the 
nasal vestibule, the mucosa between nasal septum and lateral wall of the nose, and the 
vast absorption surface area provided by the pseudostratified columnar epithelium in the 
main vault of the nasal cavity (Quraishi et al., 1997). In comparison to traditional 
intravenous or gastrointestinal administrations, pharmacologically active drug 
components are more stable in the nasal cavity environment, exhibit superior absorption 
in nasal mucosa, avoid hepatic elimination, circumvent the blood-brain barrier, and elude 
gastrointestinal and hepatic metabolism (Pires et al., 2009). These advantages enhance 
drug bioavailability after absorption and allow sufficient medication to reach targeted 
regions.  
 
Allergic rhinitis is a medical condition characterized by irritation and inflammation of the 
mucosal membrane in the nasal cavity. It’s estimated that rhinitis affects 10%-30% of 
adults (Schoenwetter et al. 2004). Airborne allergens diffuse into the mucosal membrane 
where immune cells begin secreting antibodies as an allergenic response. These 
antibodies bind to mast cells in the mucosal membrane, causing them to secrete 
histamine, which leads to itching, swelling, and mucus secretion in the nasal cavity. The 
most common treatment for rhinitis is by anti-histamines, which block histamine 
receptors on basophils and mucus-secreting mast cells to prevent inflammation. Nasal 
injection is the most effective method for drug delivery, as anti-histamines come into 
direct contact with the mucosal layer, without needing to diffuse through vasculature.      
 
To maximize the advantages provided by nasal therapy, nasal drug delivery requires 
careful design of a nasal sprayer device. The ability of the sprayer device to deposit drug 
particles rely on fluid flow velocity, flow turbulence, deposition mechanisms between 
particles and environment, and particle properties stemming from particle density, size, 
and spray cone angle. The nasal sprayer must deliver administered drug to the posterior 
cavity for maximal absorption and avoid depositing in anterior regions where little drug 
diffuses through the mucosa. Recently, Inthavong et al. (2008) showed the major factors 
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influencing deposition – nasal cavity geometry, spray particle sizes, spray cone angles, 
insertion angle, and injected particle velocities – using a particle tracking method. The 
findings suggested that spray particle size, spray cone diameter, and insertion angle had 
significant effects on position of drug deposition. 
 
Expanding on established studies, this report focuses on the optimal injection 
velocity/flow rate, injection angle, spray cone angle, and particle diameter. This model 
incorporates the Navier-Stokes and Continuity equations for fluid flow with Lagrangian 
Particle Tracking equations for particle velocity and location to observe concentration of 
drug deposited in the anterior, middle, and posterior cavity regions.  
 
2.1 Design Objectives 
We will model drug particle deposition in a simplified nasal geometry using 
mathematical modeling. We will determine the optimal injection flow rate, injection 
angle, spray cone angle, and particle mass and size for effective deposition of Azelastine 
hydrochloride in the posterior nasal cavity. The parameters are defined below in Problem 
Formulation. We will also observe how Azelastine is cleared from the mucosal layer. 
These findings will inform future nasal spray designs. Our goal is to identify what 
combination of parameters defined will lead to optimal drug deposition in the targeted 
nasal mucosa. 
 
3. Problem Formulation 
 
3.1 Terms Defined 
Flow Rate – flow velocity of the particles as they enter the nasal cavity.  
Particle Mass – the mass of the liquid particles injected by the nasal spray. Particle mass 
will depend only on particle diameter as the density is assumed to remain constant at 
1000 kg/m
3
. Particle diameters range from 10μm to 50μm.  
Injection Angle – the angle at which the particles leave the spray nozzle and enter the 
nasal cavity 
Cone Angle (Cone Diameter) – the angle from the nozzle at which particle spreading 
occur. In other words, it is the spray angle at which the liquid stream is dispersed into 
distinct particles. The cone diameter at which particle dispersion occurs is a function of 
cone angle. 
 
3.2 Schematic 
The anatomical image and geometry of the nasal passageway, shown in Figure 1, is 
simplified to a two dimensional geometry to reduce complexity in calculation. The 
simplified geometry consists of four distinct regions – the anterior, the middle, the 
posterior, and the escape. This model incorporates the appropriate parameters that 
determine whether spray particles will avoid being trapped in the anterior cavity and 
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reach the posterior areas instead. To account for computational discrepancies caused by 
sharper edges in a previous simplification, the design was adjusted accordingly using 
smooth boundary curves in Figure 2. This provided a more accurate representation of the 
true geometry and offered enhanced computational results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anterior 
(20mm) 
Middle 
(30mm) 
Posterior 
(35mm) 
Escape 
(15mm) 
Figure 2. Simplified geometry of the nasal cavity and the flow boundary conditions. The cavity was 
divided into four regions based on distance along the x axis. The inlet velocity shown is one of the 
boundary conditions used in our model. The complete list of the nostril velocity can be found in table 3. 
𝒖𝒙 = 𝟑.𝟏𝟎 ∗ 𝐬𝐢𝐧 
𝝅𝒕
𝟐   
𝒖𝒚 = 𝟏.𝟏𝟑 ∗ 𝐬𝐢𝐧(
𝝅𝒕
𝟐 ) 
𝑷 = 𝟎 𝒑𝒂 
No slip wall 
Figure 1. Anatomical image of a healthy human’s nasal cavity. The figure on the left shows current 
drug delivery in the nasal cavity in yellow. The figure on the right displays more efficient and improved 
drug deposition as seen by the nasal cavity being completely full.  
[http://www.optinose.no/nasal-delivery/nasal-delivery-challenges] 
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3.3 Mesh 
Based on schematic from Figure 3, an unstructured mesh with an “extra fine” mesh size 
was applied to the geometry. A finer mesh was used around the edges to make sure 
particles were deposited in the proper regions along the boundary. The mesh contains a 
total of 5563 elements. 
 
 
3.4 Governing Equations 
Fluid intake through the nose was modeled as a 2D laminar flow using the Navier-Stokes 
equation and the continuity equation for steady state conditions (Inthavong et al., 2008). 
These equations are built into COMSOL as a module. The 2D species mass transport 
with the diffusive term and a zero order reaction was used.  
 
Navier-Stokes and Continuity for Air Flow  
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Figure 3. Unstructured mesh of nasal cavity model. Mesh contains 5563 elements. 
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Lagrangian Particle Tracing for Particle Velocity and Location   
  
   
  
=  [  (      )]   
 
  = 
         
        
 
 
   =     
|      |
  
 
Species Mass Transfer 
   
  
=    (
    
   
  
    
   
)     
 
  =  (     )   
 
3.5 Boundary Conditions 
Flow Boundary Conditions 
● Nasal wall is rigid 
● Effect of mucus is negligible 
● No-slip condition at the cavity wall 
○ Velocity of fluid at cavity wall is zero 
● Average inspiratory flow rate varying from 20 to 40 L/min 
● Pressure at outlet  is assumed to be 0 Pa 
Diffusion Boundary Conditions 
 Mucus layer completely insulated from nasal cavity and epithelium 
 
3.6 Assumptions 
Flow assumptions were adapted from Inthavong et al. (2008). 
Fluid Flow 
1. Laminar flow 
2. Air flow in nasal cavity is modeled as Newtonian and incompressible fluid. 
Particles 
1. All particles are assumed to be spheres of the same size  
2. Particles are trapped with 100% efficiency once in contact with the cavity wall 
3. Negligible gravitational forces on particles 
Mass Transport 
1. Drug does not evaporate from mucosal layer into the nasal cavity 
2. Drug elimination modeled as zero order elimination reaction 
3. Convective flow ignored at the boundary and out of the mucus layer is 
ignored 
4. Mucosal layer thickness is constant throughout the boundary 
5. Drug concentration is initially constant across the width of the mucosal layer.  
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3.7 Input Parameters 
The input parameters and units used are shown in Table 1, 2, 3, and 4. Table 1 consists of 
constant values.  
Table 1. Constant Input Parameters   
Particle Density    1000 kg/m
3
 (Inthavong et al., 2008) 
Initial Particle Velocity 
up,x 0 m/s (Inthavong et al., 2008) 
up,y 0 m/s (Inthavong et al., 2008) 
Initial Fluid Velocity 
ug,x 0 m/s (Inthavong et al., 2008) 
ug,y 0 m/s (Inthavong et al., 2008) 
Drag Force Coefficient Cd 0.44 (Holland et al., 1995) 
Fluid Viscosity at 290K    1.7985 x 10
-5
 kg/m·s (Datta and Rakesh et al., 2008) 
Fluid Density at 290 K    1.2177 kg/m
3
 (Datta and Rakesh et al., 2008) 
Drug Diffusivity in 
mucosal layer 
D 1.5 x 10
-10
 m
2
/s (Desai et al., 1991) 
Partition Coefficient K 293.7 https://www.ebi.ac.uk/chembldb/index.php/ 
compound/inspect/CHEMBL639 
Drug Degradation Rate kd 6.0312*10
-6
 s
-1
 https://www.ebi.ac.uk/chembldb/index.php/ 
compound/inspect/CHEMBL639 
Total Drug Injected 
During One Spray 
c0 3.59 x 10
-4
 mmol https://www.ebi.ac.uk/chembldb/index.php/ 
compound/inspect/CHEMBL639 
 
Table 2 consists of different input parameters that were used in the sensitivity analysis. 
 
Table 2. Varying Constant Input Paramters (Inthavong et al., 2008) 
Particle Diameter dp 5, 10, 20, 50 µm 
Spray Cone Diameter din 2, 4, 6, 10 mm 
Flow Rates Q 20, 30, 40 L/min 
Average Velocity uavg 2.1,3.15,4.2 m/s 
 
Table 3 consists of equations representing velocity as a function of time with different 
insertion angles. These time-dependent inlet velocities were set as boundary conditions at 
the nostril. We used a sine function to model the breathing pattern more accurately.  
 
Table 3. Velocity as a Function of Time Relative to Insertion Angles 
Insertion Angle (º) Flow Rate (L/min) 
  20 
(uavg =2.1 m/s) 
30 
(uavg =3.15 m/s) 
40 
(uavg =4.2 m/s) 
20 
ux  .  ∗     (    )  .  ∗     (
  
  )  .  ∗     (
  
  ) 
uy  .  ∗     (    )  .  ∗     (
  
  )  .  ∗     (
  
  ) 
30 
ux  .  ∗            .  ∗     (
  
  )  .  ∗     (
  
  ) 
uy  .  ∗     (    )  .  ∗     (
  
  )  .  ∗     (
  
  ) 
45 
ux  .  ∗     (    )  .  ∗     (
  
  )  .  ∗     (
  
  ) 
uy  .  ∗     (    )  .  ∗     (
  
  )  .  ∗     (
  
  ) 
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Table 4 consists of mucosal clearance rates that were used to model drug elimination 
from the mucus layer. Rates were considered constant based on in vivo experimental data 
from Hua (2010). Note that these rates are based from a mouse model with elimination of 
nanoparticles in isotonic saline.  
 
Table 4. Mucosal Clearance Properties 
Time Mucosal Clearance Rate (kc)  
0 to 10 min 1.7% min
-1 (Hua et al., 2010) 
10 to 60 min 0.3% min
-1 (Hua et al., 2010) 
 
3.8 Mass Transport Formulation 
After performing the flow simulation, species mass transport calculations were done in 
the mucosal layer. The mucosal layer was estimated to be 0.5mm in thickness (Marttin et 
al.1998). The particle distribution along boundary was calculated by interpolating particle 
deposition along the boundary. Particle coordinates were determined (see Appendix 8.2) 
and were the basis for the areas of 25 subdomains in mucosal layer where particles had 
deposited (Figure 4, Table 5). Each particle coordinate was positioned at the midpoint of 
the width of each subdomain. By dividing the total drug injected by the mucus area, the 
total drug concentration was determined to be 4.03 mmol/m
2
. Each subdomain contained 
a fraction of the initial concentration, based on the area of the subdomain.  
 
Drug removal was assumed to occur by two modes: elimination from mucus turnover and 
drug degradation. Hua et al. observed that mucosal clearance occurs at 2 relatively 
constant rates within the first hour. Therefore, we used a zero order reaction to model 
drug elimination from the mucosal layer. This reaction incorporated the elimination rate 
and the initial concentration in each subdomain.  
 
Table 5 consists of mucosal subdomain areas and initial concentration determined by 
particle distribution along the boundary. Note that the particle distribution in this model 
was based on the flow model with optimal deposition parameters (40L/min, 45
o
 insertion, 
6 mm cone, 50 µm particle diameter), where all particles had deposited in the cavity.  
 
Table 5. Mucosal Subdomain Initial Concentrations Along The Upper Boundary 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
Area  
(10
6 
m
2
) 
5.06 2.1 1.58 1.33 1.26 0.921 0.834 0.736 0.622 0.618 0.573 0.537 0.535 
Concentration  
(10 mmol/m
2
) 
0.028 0.068 0.090 1.08 1.13 1.56 1.71 1.94 2.29 2.31 2.49 2.66 2.66 
 14 15 16 17 18 19 20 21 22 23 24 25 Total 
Area  
(10
6 
m
2
) 
0.505 0.536 0.533 0.530 0.537 0.556 0.553 0.556 0.572 0.618 0.610 4.02 26.8 
Concentration  
(10 mmol/m
2
) 
2.82 2.66 2.66 2.73 2.65 2.56 2.57 2.56 2.48 2.29 2.32 0.354 50.4 
11 
 
 
 
 
 
 
4. Results and Discussion 
 
4.1 Results 
We ran our model for a range of flow rates from 20 L/min to 40 L/min, insertion angles 
from 20° to 45°, spray cone diameters from 2mm to 8mm, and varying particle diameters 
from 10μm to 50μm. Comparing combinations of these parameters, an optimal 
combination for maximum drug deposition was achieved at 40 L/min flow rate with a 45° 
insertion angle and a 90° (6mm) cone angle. Figure 5 shows the contour plot for fluid 
flow through nasal cavity based on said parameters.  
 
 
Figure 5. Contour map of nasal cavity with fluid flow, drug deposition, and particle tracking. The 
optimal parameters of 40 L/min flow rate, with a 45° insertion angle and a 90° cone angle (6mm) were 
used. 
Figure 4. Schematic of mucosal layer divided into multiple subdomains. Note that only the top 
boundary was considered as no particles deposited along the bottom boundary.  
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Furthermore, the model was expanded to test diffusion and elimination of the drug after 
deposition into the surrounding mucosal layer. Figure 6 shows the concentration profile 
after 1 hour based on the particle distribution profile from the flow simulation with 
optimal parameters. The average drug concentration distribution in each subdomain is 
given in Figure 7. 
 
 
 
 
 
 
0
0.005
0.01
0.015
0.02
0.025
0.03
0.035
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08
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a
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o
n
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m
o
l/
m
3
) 
Arc-Length (m) 
Concentration Deposited Along Upper 
Mucosal Boundary 
t = 0
t = 1 hr.
Figure 6. Contour map of drug concentration after 1 hour. This simulation was based on the drug 
deposition from the optimal case shown in Figure 4.  
Figure 7. Plot of average drug concentration in each subdomain at t=0 and t=1hr. Note that 
subdomains were only evaluated where drug was deposited at the upper boundary, not the entire 
mucosal layer. Over time, drug is eliminated and diffuses out resulting in a flatter profile. 
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The contour map and concentration profile suggest that diffusion will have a role in 
spreading drug throughout mucosal layer. However, the rate of elimination is much too 
fast for the drug concentration to have a completely even spread throughout the layer. 
From the total average concentration plot (Figure 8), one can see that the drug is 
eliminated quickly in the first 10 minutes and more slowly after 10 minutes. Our model 
predicts that 32.3% of the drug is eliminated after 1 hour. 
 
 
 
 
 
4.2 Limitation of Results 
There were several limitations to our results. The model was limited to one cycle of 
breathing because COMSOL would have had difficulty converging and solving the 
problem. The initial fluid velocity was assumed to be 0 m/s because if the initial velocity 
was significantly higher it would be more likely for the drug particles to deposit in the 
anterior region instead of the middle and posterior region. This initial fluid velocity value 
was also not realistic. We are constantly breathing in and out so it would be impossible 
for the velocity at the inlet of the nasal cavity to ever be 0 m/s.  
 
Another limitation was in our diffusion analysis. The drug concentration profile was 
determined by interpolating particle deposition, instead of using a more accurate, 
continuous distribution. Increasing the number of particles would provide more accurate 
results, but becomes more time intensive. Also, flow effects were not considered and 
elimination was considered as a zero order reaction, while in reality elimination also must 
0
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Figure 8. Plot of average drug concentration in the entire mucosal layer over time (including the areas 
for the top and bottom layers of nasal cavity). The fastest rate of elimination occurs in the first 10 
minutes. 
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depend on drug concentration. Yet another limitation was assuming drug concentration 
was homogeneous in each subdomain. 
 
4.3 Accuracy Check 
To confirm the accuracy of our flow results, we compared with a similar computational 
model (Inthavong et al., 2008) and an experimental model (Cheng et al., 2001). 
Specifically, we looked at particle deposition along different sections of the nasal 
boundary. Using the postprocessing particle tracing module, 50 particles at 10μm 
diameter were released for 2 seconds. The nasal cavity, depicted in Figure 9, was divided 
into 4 sections: anterior, middle, posterior, and escape. Our model assumed perfect 
particle entrapment along the boundary.  
 
 
 
 
 
Table 6. Percentage of Drug Particles Captured in Each Nasal Region 
 Anterior Middle Posterior Escape 
Number of 
Particles 
30 2 4 14 
Fractional 
Deposition 
0.6 0.04 0.08 0.28 
 
Ithavong, 
2008 
0.538 0.036 0.038 0.388 
Error +11.5% +11.1% +111% -27.8% 
 
Chen, 2003 0.375 0.625 0 0 
 
  
Escape 
Anterior 
Middle 
Posterior 
Figure 9. Accuracy check of nasal cavity model. The number of drug particles stuck to the wall of the 
nasal cavity in each of the four regions – anterior, middle, posterior, and escape – are shown. 
Parameters used were equivalent to those used by Inthavong. 
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Our results shown in Table 6 have a similar trend as seen by Ithavong et al., (2008). Most 
of the particles either deposited in the anterior region or escaped through the outlet. The 
relatively high error values can be accounted for by the small differences in geometry. 
Better accuracy can be achieved with more particles, but visualization and particle 
tracking would be significantly more difficult.   
 
On the contrary, our results were significantly different from to Cheng et al., (2003). The 
middle portion, in Cheng’s findings, had absorbed more particles. A number of factors 
that could have contributed to variation from experimental data include particle 
diameters, a 3D geometry, a lower inlet flow rate, and turbulence. Our particle deposition 
was very sensitive to particle diameter as seen in our sensitivity analysis. The 3D 
geometry would increase the surface area and consequently cause most of the particles to 
become entrapped before leaving the nasal cavity.   
 
Unfortunately, we could not find any other studies that analyzed elimination of anti-
histamines in the mucosal layer. Measuring total drug concentration in the nasal cavity 
over time is still very difficult to achieve in vivo. However, our cumulative drug 
clearance (32.3%) did compare favorably with those observed by Hua et al. 2010 
(33.2%), who performed mucosal clearance tests of isofluorane at an equal concentration 
in the mouse model.  
 
4.4 Sensitivity Analysis  
Our sensitivity analysis analyzed the effects of four parameters on drug deposition: flow 
rate, insertion angle, cone diameter, and particle diameter. Our analysis determined the 
optimal parameters for deposition in the middle and posterior regions of the nose. 
Parameter values were adapted from Inthavong et al., (2008). The model implemented at 
three inlet flow rates (20, 30, 40 L/min), which were converted to flow velocity as shown 
in Appendix A. Insertion angle was varied by changing the x and y components of the 
flow velocity at the inlet. Parameters in the particle-tracing module were varied to 
account for different cone and particle diameter. Combinations of four different insertion 
angles and cone diameters were tested (Figure 10). 
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Our results showed the most deposition occurring at 20L/min with a 20° insertion angle. 
Deposition also seemed to occur more frequently at higher cone diameters. Particle 
diameter directly increased the particle mass when the density remained constant. Next, 
the optimal combination for each flow rate was tested with varying particle diameter 
sizes. Our results are shown in Figure 11.  
Figure 10. Sensitivity analysis of injection angle and 
cone diameter on particle deposition in the middle and 
posterior of the nasal cavity at various flow rates. 
Maximum particle deposition occurred at 20L/min flow 
rates at a 20° insertion angle. Larger cone angles of 
6mm and 8mm were most optimal. Insertion angles 
were applied by varying the x and y components of 
inlet flow. Angles are degrees from the axis normal to 
the inlet boundary. Cone diameters were applied by 
varying the particle release boundary in the particle 
tracing module. All values were calculated using 10um 
particle diameter. The model with 40L/min flow and 
20° insertion angle did not converge.  
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At lower flow rates, increased diameter increases particle deposition in the nasal cavity 
only by a little. This occurred because the high particle mass caused particle to move less 
directly along the flow and prevent escape through the outlet, but the particle was too 
heavy for the low flow rate to bring the drug to the target location. At lower masses, there 
was more circulation as particles escaped along Eddy currents occurring along the sides 
of the main flow path. At high flow rates, deposition increased with particle diameter as 
increased velocity allowed particles to have more momentum to escape the flow path and 
deposit along the top boundary. By varying the angle, one can “aim” the particle 
deposition path. Our model shows that maximum particle deposition at the middle and 
posterior regions occur when “aiming” the flow at a 45° insertion angle.    
 
 
 
 
 
 
 
Figure 11. Sensitivity analysis of particle 
diameter on particle deposition in the four nasal 
cavity regions. Increased diameter resulted in 
higher particle mass. At lower flow rates, 
increased particle diameter resulted in less 
particle escape. As the flow rate, injection angle, 
and particle diameter increased, more particles 
deposited inside the nasal cavity. All values were 
calculated using a 6mm cone angle.   
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5. Conclusion and Design Recommendations 
 
5.1 Conclusion 
This study demonstrated the significance of insertion angle in determining deposition of 
spray particles in the middle and posterior regions of the nasal cavity. For a flow rate of 
20 L/min, maximal deposition occurred with an insertion angle of 20°. However, when 
we varied flow rate from 20 L/min to 30 L/min to 40 L/min, maximum particle 
deposition occurred at insertion angle of 45°. As the particle diameter increased, the mass 
of the drug increased as well. This change required a higher flow rate and larger insertion 
angle for the drug to be deposited effectively in the middle and posterior regions. Also, 
our mass transport simulation showed that drug elimination occurs much too rapidly 
before the drug concentration can evenly spread by diffusion.  
 
5.2 Implications and Relevance  
Our model demonstrated the importance of the size of drug particles, which ultimately 
decides the flow rate and insertion angle most suitable for administration. While the 
typical drug particle diameter should never be as large as 50μm but not too small, a size 
of 10 or 20μm is also reasonable. This consequently dictates a lower flow rate and a 
smaller insertion angle to prevent too many particles from escaping through the outlet. 
 
This finding helps considerations for drug dosages when evaluating the reproducibility 
and precision of the delivery of the spray. In the case of Azelastine hydrochloride, the 
recommended dosage for adults and children 12 years of age and older is one or two 
sprays per nostril twice daily (Berger, 2009). Each spray, delivering 137 μg of drug, 
significantly reduces histamine release and biochemical regulators of inflammatory 
response. Thus, our parameters can dictate an effective combination that will deliver the 
prescribed amount to targeted areas.  
 
In addition, the cone angle and insertion angle parameters are useful in developing head 
positioning techniques for administering Azelastine hydrochloride. The current positions 
are: 1) head neutral (0-10° to the vertical plane), spray at 30° to the plane of face and 2) 
head forward (60-90° to the vertical plane), spray at 90° to the plane of face (Batemen et 
al. 2002). Bateman pointed out that neither technique is superior to the other and both fail 
to deliver optimal distribution of drug to posterior nasal cavity. Our findings can improve 
clinical studies and provide proper insertion and cone angles for maximal delivery of 
drug to the posterior regions.  
 
Most importantly, this study paves a way for nasal sprays to be used in medical 
treatments outside of chronic rhinitis and respiratory ailments. In past and recent 
scientific news nasal sprays have been involved in a range of treatments. They have been 
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used to incorporate the use of vasopressin to treat diabetes insipidus. Results have shown 
that the method of treatment allows the drug to stay in blood plasma longer and its 
absorption is effective, non-sensitive, and non-irritating. It could be used as an in between 
treatment for patients with severe diabetes (Dashe, 1964). Also nasal decongestants can 
be used to significantly reduce the frequency of snoring (Braver et al., 1995). Most 
recently, research has begun for the use of intranasal fentanyl for treating acute pain. The 
benefit of this administration is an immediate effect on the central nervous system and it 
can be administered to children as well. However, the onset time so far is longer than the 
basic IV treatment. More studies have to be done to incorporate pharmacokinetics to 
allow faster and more efficient absorption. Some other hypotheses being worked on now 
involve a nicotine replacement treatment by nasal spray instead of a patch or pill, and a 
nose to brain drug delivery pathway to avoid the blood brain barrier. Our results on 
optimal parameters for maximum absorption will help with the amount of research going 
into nasal sprays utilizing different drugs to treat various types of illnesses and the 
pharmacokinetics that come along with the types of drugs used, which need to be studied 
and taken into account.  
 
5.3 Design Recommendations 
Based on our study we determined that effective drug deposition for a moderately sized 
around 10 to 20 µm drug particle requires a flow rate of approximately 20 L/min and an 
insertion angle of 20°. For most drug particles sized at 50 µm, a flow rate of 40 L/min 
and insertion angle of 45º showed higher effectiveness. The spray cone diameter should 
always be at least 6 mm, which is a 90° spray angle. We would recommend designers of 
nasal sprays to make the nozzle longer and possibly narrower. The longer length would 
help achieve the small insertion angle. On the other hand, the outlet of the nozzle for the 
drug particles should be designed for the particles to produce the optimal spray cone 
diameter. Also, nasal spray development should not put too much focus on improving 
diffusion because this rate is several orders of magnitude slower than the mucosal 
clearance rate.  
 
5.4 Design Constraints 
Although our model found the optimal spray and drug parameters of Azelastine, the 
values used may not apply to other drugs. Different drug applications have different 
particle densities, drug diffusion coefficients, and particle sizes. The variability in particle 
densities would affect the modeling of drug deposition. If the drug is lighter, a lower inlet 
velocity is required with a lower insertion angle. But if the drug is heavier, a higher flow 
rate along with a higher insertion angle can be used to achieve the same percentage of 
drug deposition in the middle and posterior regions. Also the difference in diffusion 
coefficients may be representative of the mechanisms of different drugs. However, it is 
difficult to obtain the values of these diffusion coefficients from experimentation. 
Another factor to consider is the mucosal layer. This layer constantly changes its 
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chemical composition and thickness, affecting viscosity, drug distribution, and therefore 
diffusion rates. Some current intranasal applications do not deposit particles at a fairly 
constant particle size. This high degree of variability brings up questions on how accurate 
any computational model can be in determining a definite set of optimal parameters. 
 
Another constraint to our model was using 2D geometry instead 3D. With modern day 
technology, it is easier to scan a patient’s nasal cavity to serve as a 3D model. However, 
the governing equations and input parameters used for flow velocity would be more 
complex. This would change the equations in our model and the solution time would be 
much longer. On the other hand, a 3D model would provide observations and results that 
would be much more accurate than our 2D geometry. Significant effort should be put into 
developing a 3D model as it’s clear from anatomical imaging that the 3D model would 
have a much greater surface than a 2D model projected as a slab. Surface area is arguably 
the most important difference will significantly affect where particles get deposited. 
While it may be challenging to develop a functional 3D model, this is the clear next step 
in modeling intranasal delivery  
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6. Appendix A: Mathematical Statement of Problem 
 
6.1 Force exerted on particles for evaluation of particle trajectories 
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Plug in th Fd equation  into the force equation, we get 
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This derived force equation was inputted into the equation of motion of the particle 
tracing function in COMSOL to obtain the pattern of drug deposition (see figure 9.) 
 
 
6.2 Derivation of boundary condition at a nostril 
 
Flow rate in human nasal passageway ranges between 20 and 40 L/min which correspond 
to average inlet velocity of 2.1 m/s and 4.2 m/s (Inthavong et al., 2006). Because the 
physiological flow velocity is not constant over a breathing cycle, we sought to apply a 
time-dependent velocity to the boundary condition at the inlet, while keeping the average 
velocity at the physiological rates.   
  
To derive the inlet velocity equation, we first looked at the general form of sine equation.  
     
     =           ∗    (     ) 
    
 where u is velocity 
  t is time 
  T is a period of one breathing cycle (which is 4 seconds for human) 
 
We next calculated the function of average velocity 
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Note that we modeled only half of the breathing cycle. Our final time is therefore equal to 
2 seconds 
 
          =       
 
We knew the value of average velocity and we wanted to find amplitude value. 
Rearranging the equation, we got: 
      
       =       ∗       
 
Plugging the equation of amplitude back into the original speed equation, we got: 
  
u = 
     
 
     (    ) 
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7. Appendix B: Solution Strategy 
 
7.1 Mesh Convergence 
 
Figure 12. Schematic of a nasal cavity. The red line located in the middle of the cavity is where the 
average velocity is taken for the mesh convergence analysis 
 
The mesh convergence analysis was performed based on the average value of the velocity 
along the red line shown in Figure 12 because the velocity field varies the most in this 
region. The average velocity was evaluated at eight different mesh sizes, and the solution 
began to converge when number of elements reached 5563 (Figure 13). This mesh was 
used as our model to evaluate the drug deposition for our final solution.  
 
 
Figure 13. Mesh convergence analysis of nasal cavity. 
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 Mesh convergence was also performed on the mucosal layer subdomain (Figure 
14). Analysis was performed at 5 different mesh sizes by integrating drug concentration 
across the mucosal domain after 1 hour. The solution converges at about 5000 elements 
and our mesh contained 5678 elements. This mesh was used in our mass transport model. 
 
  
Figure 14. Mesh convergence analysis of mucosal layer.  
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8. Appendix C: Software Implementation 
 
8.1 Particle Tracing 
 
To obtain particle trajectory plot, we used a COMSOL particle tracing feature 
under post-processing. This function requires five major input parameters including force 
equation derived in section 6.1, particle mass, particle initial positions, and initial velocity 
of the particles. These respective parameters indicated by number 1-5 were input into the 
particle tracing window shown in Figure 15.  
 
 
 
Figure 15. COMSOL particle tracing window. Number 1-5 indicate the five required input parameters: 
force, particle mass, particle radius, particle release positions, and initial velocity, respectively 
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8.2 Particle Coordinates 
  
 To determine particle position along the boundary, we exported our model in 
FEM format into MATLAB. The following code was used to run the particle simulation 
in MATLAB for 25 particles and extract particle position (Figure 16). 
 
 
Figure 16. MATLAB code for FEM simulation of particle module 
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